1,002
Views
44
CrossRef citations to date
0
Altmetric
Drug Evaluations

Clozapine use in children and adolescents

, MD & , MD
Pages 459-465 | Published online: 28 Jan 2008

Bibliography

  • Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45(9):789-96
  • Hafner H, Nowotny B. Epidemiology of early-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci 1995;245(2):80-92
  • Krausz M, Muller-Thomsen T. Schizophrenia with onset in adolescence: an 11-year followup. Schizophr Bull 1993;19(4):831-41
  • Nicolson R, Rapoport JL. Childhood-onset schizophrenia: rare but worth studying. Biol Psychiatry 1999;46(10):1418-28
  • Childs B, Scriver CR. Age at onset and causes of disease. Perspect Biol Med 1986;29(3 Pt 1):437-60
  • Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin Pharmacother 2006;7(13):1739-48
  • Kane JM. Clinical efficacy of clozapine in treatment-refractory schizophrenia: an overview. Br J Psychiatry Suppl 1992;17:41-5
  • McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163(4):600-10
  • Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079-87
  • Davies LM, Jones PB, Barnes TR, et al. Cost-effectiveness of first-v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 2007;191:14-22
  • Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209-23
  • Nasrallah HA. The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. J Clin Psychiatry 2007;68(Suppl 1):5-11
  • Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60(6):553-64
  • Woerner MG, Robinson DG, Alvir JMJ, et al. Clozapine as a first treatment for schizophrenia. Am J Psychiatry 2003;160(8):1514-6
  • Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology 2003;28(5):995-1003
  • Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol 2007;27(4):369-73
  • Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156(2):286-93
  • Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 2001;158(3):360-9
  • Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006;20(5):389-409
  • Baldessarini RJ, Gardner DM, Garver DL. Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry 1995;52(12):1071-2
  • Garver DL. Evolution of antipsychotic intervention in the schizophrenic psychosis. Curr Drug Targets 2006;7(9):1205-15
  • Rapoport JL, Gogtay N. Brain neuroplasticity in healthy, hyperactive and psychotic children: insights from neuroimaging. Neuropsychopharmacology 2008;33(1):181-97
  • Green SM, Sherwin TS. Incidence and severity of recovery agitation after ketamine sedation in young adults. Am J Emerg Med 2005;23(2):142-4
  • Farber NB, Newcomer JW, Olney JW. The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease. Prog Brain Res 1998;116:421-37
  • Thompson PM, Vidal C, Giedd JN, et al. Mapping adolescent brain change reveals dynamic wave of accelerated gray matter loss in very early-onset schizophrenia. Proc Natl Acad Sci USA 2001;98(20):11650-5
  • Towbin KE, Dykens EM, Pugliese RG. Clozapine for early developmental delays with childhood-onset schizophrenia: protocol and 15-month outcome. J Am Acad Child Adolesc Psychiatry 1994;33(5):651-7
  • Mozes T, Toren P, Chernauzan N, et al. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry 1994;33(1):65-70
  • Remschmidt H, Hennighausen H, Clement HW, et al. Atypical neuroleptics in child and adolescent psychiatry. Eur Child Adolesc Psychiatry 2000;9(Suppl 1):I9-19
  • Remschmidt H, Fleischhaker C, Hennighausen K, Schulz E. Management of schizophrenia in children and adolescents. The role of clozapine. Paediatr Drugs 2000;2(4):253-62
  • Kumra S, Frazier JA, Jacobsen LK, et al. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 1996;53(12):1090-7
  • Shaw P, Sporn A, Gogtay N, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry 2006;63(7):721-30
  • Kumra S, Kranzler H, Gerbino-Rosen G, et al. Clozapine and “high-dose” olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry 2007
  • Teicher M, Barbar N, Gelbard H, et al. Developmental differences in acute nigrostriatal and mesocorticolimbic system response to haloperidol. Neuropsychopharmacology 1993;9(2):147-56
  • Lewis R. Typical and atypical antipsychotics in adolescent schizophrenia: efficacy, tolerability, and differential sensitivity to extrapyramidal symptoms. Can J Psychiatry 1998;43(6):596-604
  • Kranzler HN, Kester HM, Gerbino-Rosen G, et al. Treatment-refractory schizophrenia in children and adolescents: an update on clozapine and other pharmacologic interventions. Child Adolesc Psychiatr Clin N Am 2006;15(1):135-59
  • Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulocytosis. Incidence and risk factors in the United States. N Engl J Med 1993;329(3):162-7
  • Kennedy E, Kumar A, Datta S. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database Syst Rev 2007;3:CD004027
  • Gerbino-Rosen G, Roofeh D, Tompkins DA, et al. Hematological adverse events in clozapine-treated children and adolescents. J Am Acad Child Adolesc Psychiatry 2005;44(10):1024-31
  • Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 1991;148(2):231-5
  • Miller DD, Fleming F, Holman TL, Perry PJ. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry 1994;55(Suppl B):117-21
  • Potkin SG, Bera R, Gulasekaram B, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 1994;55(Suppl B):133-6
  • Kronig MH, Munne RA, Szymanski S, et al. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry 1995;152(2):179-82
  • Piscitelli SC, Frazier JA, McKenna K, et al. Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. J Clin Psychiatry 1994;55(Suppl B):94-7
  • Sporn AL, Vermani A, Greenstein DK, et al. Clozapine treatment of childhood-onset schizophrenia: evaluation of effectiveness, adverse effects, and long-term outcome. J Am Acad Child Adolesc Psychiatry 2007;46(10):1349-56
  • Andreasen NC. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand 2006;113(2):81
  • Martin RL, Cloninger CR, Guse SB. Frequency and differential diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry 1985;46(11 Pt 2):9-13
  • Braga RJ, Mendlowicz MV, Marrocos RP, Figueira IL. Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 2005;39(4):409-14
  • Pallanti S, Quercioli L, Hollander E. Social anxiety in outpatients with schizophrenia: a relevant cause of disability. Am J Psychiatry 2004;161(1):53-8
  • Tossell JW, Greenstein DK, Davidson AL, et al. Stimulant drug treatment in childhood-onset schizophrenia with comorbid ADHD: an open-label case series. J Child Adolesc Psychopharmacol 2004;14(3):448-54
  • Sporn A, Gogtay N, Oritz AR, et al. Clozapine-induced neutropenia in children: management with lithium carbonate. J Child Adolesc Psychopharmacol 2003;13(3):401-4
  • Alper K, Schwartz KA, Kolts RL, Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007;62(4):345-54
  • Chengappa KN, Shelton MD , Baker RW, et al. The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 1994;55(4):142-5
  • Chengappa KN, Shelton MD, Baker RW, et al. Clozapine-induced akathisia in children with schizophrenia. J Child Adolesc Psychopharmacol 2002;12(4):347-9
  • Wudarsky M, Nicolson R, Hamburger SD, et al. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J Child Adolesc Psychopharmacol 1999;9(4):239-45
  • Baptista T, Hernandez L, Prieto LA, et al. Metformin in obesity associated with antipsychotic drug administration: a pilot study. J Clin Psychiatry 2001;62(8):653-5
  • Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry 2002;159(4):655-7
  • Dervaux A, Cazali J. Clozapine and amisulpride in refractory schizophrenia and alcohol dependence. J Clin Psychopharmacol 2007;27(5):514-6

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.